Literature DB >> 24425106

Clinicopathological and prognostic significance of hypoxia-inducible factor-1α in esophageal squamous cell carcinoma: a meta-analysis.

Wei Ping1, Wei Sun, Yukun Zu, Wenshu Chen, Xiangning Fu.   

Abstract

Published literatures on the prognostic value of hypoxia-inducible factor-1α (HIF-1α) overexpression in esophageal squamous cell carcinoma (ESCC) are conflicting and heterogeneous. We performed a meta-analysis to more precisely evaluate the clinicopathological and prognostic value of HIF-1α in patients with ESCC. Searches were applied to MEDLINE, Pubmed, Embase, Cochrane Library, Web of Science, and Chinese BioMedical Literature Databases until September 10, 2013, without language restrictions. The pooled hazard ratios (HRs) and odds ratios (ORs) with corresponding 95 % confidence intervals (CIs) were used to estimate the effects. Twelve studies with 942 ESCC patients were selected to evaluate the correlation between HIF-1α and overall survival (OS), disease-free survival (DFS), response to chemoradiation (RC), and clinicopathological features. HIF-1α overexpression was significantly associated with poor OS (HR 1.78, 95% CI 1.41-2.24), DFS (HR 1.91, 95% CI 1.15-3.18), and RC (HR 3.56, 95% CI 1.68-7.53). Besides, HIF-1α overexpression was significantly associated with stage (OR 2.90, 95% CI 1.97-4.27), lymph node metastasis (OR 1.86, 95% CI 1.39-2.49), depth of invasion (OR 2.45, 95% CI 1.24-4.86), lymphatic invasion (OR 2.28, 95% CI 1.46-3.56), distant metastasis (OR 2.04, 95% CI 1.19-3.50), and vascular endothelial growth factor (OR 3.67, 95% CI 1.81-7.46). Our results indicate that HIF-1α overexpression can potently predict the poor prognosis and chemoradiation resistance for ESCC. Large prospective studies with multivariable survival analyses are now needed to confirm the clinical utility of HIF-1α as an independent prognostic marker.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24425106     DOI: 10.1007/s13277-013-1579-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  51 in total

1.  Prognostic value of hypoxia inducible factor 1α in esophageal squamous cell carcinoma.

Authors:  P C Munipalle; Y K S Viswanath; P A Davis; D Scoones
Journal:  Dis Esophagus       Date:  2010-11-12       Impact factor: 3.429

2.  Hypoxia-inducible factor 1 alpha (HIF-1α) as a prognostic indicator in patients with gastric tumors: a meta-analysis.

Authors:  Zhi-Gang Zhang; Qiu-Ning Zhang; Xiao-Hu Wang; Jin-Hui Tian
Journal:  Asian Pac J Cancer Prev       Date:  2013

3.  Correlation of hypoxia inducible factor-1alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer.

Authors:  Miwako Katsuta; Masao Miyashita; Hiroshi Makino; Tsutomu Nomura; Seiichi Shinji; Kiyohiko Yamashita; Takashi Tajiri; Mitsuhiro Kudo; Toshiyuki Ishiwata; Zenya Naito
Journal:  Exp Mol Pathol       Date:  2005-01-07       Impact factor: 3.362

4.  Significance of Twist expression and its association with E-cadherin in esophageal squamous cell carcinoma.

Authors:  Ken Sasaki; Shoji Natsugoe; Sumiya Ishigami; Masataka Matsumoto; Hiroshi Okumura; Tetsuro Setoyama; Yasuto Uchikado; Yoshiaki Kita; Kiyokazu Tamotsu; Akihiko Sakamoto; Tetsuhiro Owaki; Takashi Aikou
Journal:  J Exp Clin Cancer Res       Date:  2009-12-21

5.  Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis.

Authors:  Tatsuya Tanaka; Hideyuki Ishiguro; Yoshiyuki Kuwabara; Masahiro Kimura; Akira Mitsui; Takeyasu Katada; Midori Shiozaki; Yasuhiro Naganawa; Yoshitaka Fujii; Hiromitsu Takeyama
Journal:  J Exp Clin Cancer Res       Date:  2010-06-28

6.  2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

Authors:  Nicola J Mabjeesh; Daniel Escuin; Theresa M LaVallee; Victor S Pribluda; Glenn M Swartz; Michelle S Johnson; Margaret T Willard; Hua Zhong; Jonathan W Simons; Paraskevi Giannakakou
Journal:  Cancer Cell       Date:  2003-04       Impact factor: 31.743

7.  Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer.

Authors:  Makoto Sohda; Hitoshi Ishikawa; Norihiro Masuda; Hiroyuki Kato; Tatsuya Miyazaki; Masanobu Nakajima; Minoru Fukuchi; Ryokuhei Manda; Yasuyuki Fukai; Hideyuki Sakurai; Hiroyuki Kuwano
Journal:  Int J Cancer       Date:  2004-07-20       Impact factor: 7.396

8.  Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma.

Authors:  H Takatori; S Natsugoe; H Okumura; M Matsumoto; Y Uchikado; T Setoyama; K Sasaki; K Tamotsu; T Owaki; S Ishigami; T Aikou
Journal:  Eur J Surg Oncol       Date:  2007-06-05       Impact factor: 4.424

Review 9.  Evaluation of HIF-1 inhibitors as anticancer agents.

Authors:  Gregg L Semenza
Journal:  Drug Discov Today       Date:  2007-09-18       Impact factor: 7.851

10.  Practical methods for incorporating summary time-to-event data into meta-analysis.

Authors:  Jayne F Tierney; Lesley A Stewart; Davina Ghersi; Sarah Burdett; Matthew R Sydes
Journal:  Trials       Date:  2007-06-07       Impact factor: 2.279

View more
  17 in total

Review 1.  Hypoxia and Bone Metastatic Disease.

Authors:  Rachelle W Johnson; Miranda E Sowder; Amato J Giaccia
Journal:  Curr Osteoporos Rep       Date:  2017-08       Impact factor: 5.096

Review 2.  Hypoxia: Signaling the Metastatic Cascade.

Authors:  Erinn B Rankin; Jin-Min Nam; Amato J Giaccia
Journal:  Trends Cancer       Date:  2016-06-02

3.  Prognostic value of HIF-1α in digestive system malignancies: evidence from a systematic review and meta-analysis.

Authors:  Mohammad-Hassan Arjmand; Ali Moradi; Hamid-Reza Rahimi; Ali Es-Haghi; Abolfazl Akbari; Mohammad Reza Hadipanah; Jalil Afshar; Hassan Mehrad-Majd
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2022

4.  A cross-sectional study of obstructive sleep apnea in patients with colorectal cancer.

Authors:  Hailin Xiong; Miaochan Lao; Shuyi Zhang; Jialian Chen; Qianping Shi; Yanxia Xu; Qiong Ou
Journal:  J Gastrointest Oncol       Date:  2022-04

5.  Inhibition of HIF-1α by PX-478 suppresses tumor growth of esophageal squamous cell cancer in vitro and in vivo.

Authors:  Yingming Zhu; Yuanwei Zang; Fen Zhao; Zhenxiang Li; Jianbo Zhang; Liang Fang; Minghuan Li; Ligang Xing; Zhonghua Xu; Jinming Yu
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

Review 6.  Hypoxic control of metastasis.

Authors:  Erinn B Rankin; Amato J Giaccia
Journal:  Science       Date:  2016-04-07       Impact factor: 47.728

7.  Manganese Porphyrin and Radiotherapy Improves Local Tumor Response and Overall Survival in Orthotopic Murine Mammary Carcinoma Models.

Authors:  Mary-Keara Boss; Rebecca E Oberley-Deegan; Ines Batinic-Haberle; Geoffrey A Talmon; Jason A Somarelli; Shengnan Xu; Elizabeth A Kosmacek; Brandon Griess; Shakeel Mir; Shashank Shrishrimal; Melissa Teoh-Fitzgerald; Ivan Spasojevic; Mark W Dewhirst
Journal:  Radiat Res       Date:  2021-02-01       Impact factor: 2.841

8.  Gene and protein expression of glucose transporter 1 and glucose transporter 3 in human laryngeal cancer-the relationship with regulatory hypoxia-inducible factor-1α expression, tumor invasiveness, and patient prognosis.

Authors:  Katarzyna Starska; Ewa Forma; Paweł Jóźwiak; Magdalena Bryś; Iwona Lewy-Trenda; Ewa Brzezińska-Błaszczyk; Anna Krześlak
Journal:  Tumour Biol       Date:  2014-11-21

9.  Prognostic role of hypoxia-inducible factor-1 alpha expression in osteosarcoma: a meta-analysis.

Authors:  Hai-Yong Ren; Yin-Hua Zhang; Heng-Yuan Li; Tao Xie; Ling-Ling Sun; Ting Zhu; Sheng-Dong Wang; Zhao-Ming Ye
Journal:  Onco Targets Ther       Date:  2016-03-14       Impact factor: 4.147

10.  Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer.

Authors:  Katarzyna B Leszczynska; Greg Dobrynin; Rhea E Leslie; Jonathan Ient; Adam J Boumelha; Joana M Senra; Maria A Hawkins; Tim Maughan; Somnath Mukherjee; Ester M Hammond
Journal:  Radiother Oncol       Date:  2016-11-10       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.